Zhonghua Jie He He Hu Xi Za Zhi. Pharmacotherapeutics for the new coronavirus pneumonia

[tetano]

Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):173-176. doi: 10.3760/cma.j.issn.1001-0939.2020.03.005. [Pharmacotherapeutics for the new coronavirus pneumonia].

[Article in Chinese; Abstract available in Chinese from the publisher]

Du B¹, Qiu HB², Zhan X³, Wang YS³, Kang HYJ³, Li XY³, Wang F³, Sun B³, Tong ZH³.
Author information

Abstract

in English, Chinese
The new coronavirus pneumonia (NCP), also named as COVID-19 by WHO on Feb 11 2020, is now causing a severe public health emergency in China since. The number of diagnosed cases is more than 40,000 until the submission of this manuscript. Coronavirus has caused several epidemic situations world widely, but the present contagious disease caused by 2019 new coronavirus is unprecedentedly fulminating. The published cohorts of 2019 new coronavirus (n-Cov) are single-center studies, or retrospective studies. We here share the therapeutic experiences of NCP treatment with literature review. Combination of Ribavirin and interferon-α is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on Middle East respiratory syndrome (MERS), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable. Systemic glucocorticosteroid is recommended as a short term use (1~2 mg?kg(-1)?d(-1), 3~5 d) by the 5(th) edition National Health Commission's Regimen (Revised Edition) yet RCTs are expected to confirm the effectiveness. Inappropriate application of antibiotics should be avoided, especially the combination of broad-spectrum antibiotics, for the NCP is not often complicated with bacterial infection.


KEYWORDS:

Antibiotics; Glucocorticosteroid; New coronavirus pneumonia; Pharmacotherapeutics

PMID: 32164081 DOI: 10.3760/cma.j.issn.1001-0939.2020.03.005